Sight Sciences (SGHT) Q1 2026: Dry Eye Revenue Triples, Early Adoption Signals Scaling Path
Interventional dry eye revenue nearly tripled on surging smart lid utilization, marking a pivotal inflection for Sight Sciences’ recurring procedural model. Gross margin resilience and tight operating discipline underpinned a guidance raise, while cross-segment synergies between glaucoma and dry eye are accelerating account penetration. With reimbursement expansion and new product launches on deck, SGHT’s dual-platform strategy is entering a scale-up phase, but payer and workflow hurdles remain key watchpoints.
Summary
- Dry Eye Adoption Accelerates: Rapid utilization gains validate recurring procedural model and highlight cross-segment synergies.
- Margin and Expense Discipline Holds: Gross margins remain strong even as commercial investment ramps.
- Guidance Lift Reflects Early Momentum: Revenue outlook raised as core segments show durable growth drivers.
Business Overview
Sight Sciences is a medical device company focused on interventional eye care, specifically targeting glaucoma and dry eye disease—two of the most prevalent anterior segment conditions. The business operates two main segments: interventional glaucoma, led by the Omni technology platform, and interventional dry eye, anchored by the TierCare system and its disposable smart lids. The company generates revenue through the sale of procedural devices and recurring disposables to ophthalmology practices, with a business model increasingly tied to reimbursement and in-office procedural adoption.
Performance Analysis
Q1 2026 marked a return to double-digit revenue growth, with total revenue up 13% year over year, driven by both core segments. Interventional glaucoma, the company’s anchor business, delivered its third consecutive quarter of YoY growth, supported by increased ordering accounts and higher average selling prices, partially offset by a modest dip in utilization per account. Notably, the launch of OmniEdge, a next-generation viscoelastic delivery platform, contributed to account reactivation and new surgeon adoption.
Interventional dry eye revenue nearly tripled sequentially, reaching $1.4 million, as smart lid sales surged and average utilization per account jumped from 9 to 16. This growth was concentrated in regions with established Medicare reimbursement, and was driven by a mix of new and repeat accounts—half of which overlapped with existing glaucoma customers, reinforcing the value of cross-segment leverage. Gross margin held steady at 86%, supported by pricing and product mix, while adjusted operating expenses declined 14% as the company realized the benefits of prior cost actions.
- Smart Lid Utilization Surge: Average smart lids per active account nearly doubled, with high-volume early adopters driving initial traction.
- Omni Platform Resilience: Glaucoma revenue up 7% YoY, with new product innovation (OmniEdge) helping to offset lower per-account utilization.
- Expense Control Realized: Adjusted operating expenses fell 14% YoY, reflecting workforce reductions and disciplined investment in commercial buildout.
Cash burn moderated significantly, and the balance sheet remains robust, positioning SGHT to fund growth initiatives without near-term capital needs. The company’s guidance raise reflects confidence in both segment trajectories and validates early signs of procedural adoption in dry eye.
Executive Commentary
"We drove solid execution across both segments, interventional glaucoma and interventional dry eye. This included a third quarter in a row of revenue growth in interventional glaucoma and continued positive commercial traction in interventional dry eye, where revenue nearly doubled from the fourth quarter, representing early validation of our procedural in-office recurring revenue business model."
Paul Badawi, Co-founder and Chief Executive Officer
"We are executing against our strategic goals from a position of strength. With the operating discipline and cost structure we need to support growth, and we believe this positions us to achieve cash flow break even without the need to raise additional equity capital."
Jim Rodberg, Chief Financial Officer
Strategic Positioning
1. Procedural Model Validation in Dry Eye
Early commercial traction in TierCare, Sight Sciences’ interventional dry eye platform, is validating a recurring revenue model built on disposable smart lids and procedural integration. The sharp sequential revenue ramp and rising utilization per account suggest that practices are increasingly embedding the procedure into their workflow, especially where reimbursement is established.
2. Cross-Segment Synergy and Account Penetration
Customer overlap between glaucoma and dry eye is emerging as a strategic lever. Nearly half of dry eye adopters are existing glaucoma customers, and these accounts show higher utilization rates. This “intersection of intervention” is deepening account penetration and providing a natural cross-sell pathway as the company scales its commercial footprint.
3. Commercial Investment and Market Access
Targeted expansion of the sales and clinical support team, particularly in reimbursed geographies, is driving adoption. Management is prioritizing high-volume practices with significant Medicare populations, while also engaging with additional MACs and commercial payers to expand market access—a potential catalyst for future dry eye growth.
4. Innovation Pipeline and Product Differentiation
OmniEdge and the upcoming OmniUltra reflect a continued focus on product innovation in the implant-free microinvasive glaucoma surgery (MIGS) category. These surgeon-informed upgrades are designed to maintain SGHT’s leadership and support expansion into both combo cataract and standalone glaucoma procedures.
5. Margin and Cash Flow Discipline
Operating leverage is improving, with gross margins stable and adjusted operating expenses declining after prior cost actions. Management is balancing commercial investment with a clear path to cash flow breakeven, emphasizing high-return initiatives and prudent resource allocation.
Key Considerations
Q1 2026 marked a pivotal inflection for Sight Sciences, with early procedural adoption, robust margin performance, and strategic execution across both business lines. However, the company’s scaling trajectory remains tightly linked to reimbursement expansion and practice workflow activation.
Key Considerations:
- Reimbursement Expansion Pace: Dry eye growth is currently gated by Medicare fee schedule coverage; broader payer wins are required for step-function adoption.
- Workflow Complexity: Practice integration of procedural dry eye requires hands-on support and training, which may limit near-term velocity and require ongoing commercial investment.
- Competitive Dynamics in Glaucoma: While SGHT maintains leadership in implant-free MIGS, the segment remains competitive and sensitive to innovation cycles and surgeon preferences.
- Litigation Upside and Uncertainty: The $55 million Alcon patent judgment and ongoing royalties represent potential non-operating upside, but timing and realization remain uncertain pending appeal.
Risks
Scaling the dry eye business is highly dependent on payer adoption and successful workflow integration at the practice level. Any delays in reimbursement expansion or commercial execution could slow growth, while competitive pressures in glaucoma and macro headwinds in healthcare spending may impact both segments. The outcome and timing of the Alcon litigation also introduce financial uncertainty, and management’s ability to balance growth investments with margin discipline will be closely watched by investors.
Forward Outlook
For Q2 2026, Sight Sciences guided to:
- Low double-digit total revenue growth YoY
- Mid-single digit growth in interventional glaucoma
- Interventional dry eye revenue of $1.5 to $2 million
For full-year 2026, management raised guidance:
- Total revenue of $83 to $89 million (prior $82 to $88 million)
- Interventional glaucoma revenue of $77 to $81 million
- Interventional dry eye revenue of $6 to $8 million
- Adjusted operating expenses reaffirmed at $93 to $96 million
Management emphasized that the raised outlook is based on current reimbursement coverage and does not factor in additional payer wins, suggesting potential upside if market access expands further. The upcoming OmniUltra launch is not embedded in guidance, representing further optionality.
- Continued focus on scaling in reimbursed dry eye markets
- Ongoing investment in standalone glaucoma and commercial buildout
Takeaways
Sight Sciences is demonstrating early success in scaling a recurring procedural model in dry eye, leveraging cross-segment synergies and disciplined investment to drive sustainable growth. The path to broader adoption hinges on payer expansion and commercial execution, while innovation in glaucoma provides a foundation for continued leadership.
- Procedural Adoption Is Accelerating: Early smart lid utilization and account growth signal a scalable, recurring revenue opportunity in dry eye, but broader market access is needed for full potential.
- Margin and Cash Discipline Provide Flexibility: Expense control and robust gross margins enable investment in commercial expansion without near-term capital risk.
- Watch for Payer Wins and Product Launches: Additional Medicare and commercial coverage, as well as the OmniUltra rollout, could drive upside beyond current guidance.
Conclusion
Sight Sciences delivered a pivotal quarter, with interventional dry eye adoption outpacing expectations and core glaucoma growth holding steady. The company’s dual-platform strategy, combined with disciplined execution, positions it for sustainable growth, but the next leg of expansion will require continued progress in reimbursement and operational scaling.
Industry Read-Through
SGHT’s results underscore a broader industry shift toward procedural, device-driven care in ophthalmology, where recurring revenue models and reimbursement coverage are key to scaling adoption. The rapid early traction in dry eye highlights pent-up demand for in-office interventions, but also surfaces the operational complexity of integrating new procedures into clinical workflows. For peers in medtech and specialty device markets, the quarter validates the importance of cross-segment synergies, commercial focus on high-value accounts, and the need for payer engagement as a gating factor for growth. Ongoing litigation outcomes and innovation cycles remain industry-wide watchpoints, particularly as competitive intensity rises in both glaucoma and dry eye categories.